Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Novartis Acquires Nuclear Meds Developer in $3.9B Deal

Drug maker Novartis is purchasing a company that develops therapies and diagnostics using radio isotopes for neuroendocrine and other cancers. . . . → Read More: Novartis Acquires Nuclear Meds Developer in $3.9B Deal

Infographic – Google’s Largest Acquisitions

Our friends at Statista yesterday published this chart showing Google/Alphabet’s largest acquisitions over the years. . . . → Read More: Infographic – Google’s Largest Acquisitions

Engineered T-Cell Company Acquired for $11.9 Billion

A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion. . . . → Read More: Engineered T-Cell Company Acquired for $11.9 Billion

Genomics Company Acquires Open-Source Biomedical Platform

A company providing whole genome analysis is acquiring an enterprise developing open-source computational software for biomedical uses, such as precision medicine. . . . → Read More: Genomics Company Acquires Open-Source Biomedical Platform

Lilly Acquires Migraine Therapy Company in $960M Deal

Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms. . . . → Read More: Lilly Acquires Migraine Therapy Company in $960M Deal

Trial to Test Stem Cells for Treating Heart Failure

A clinical trial testing a treatment for heart failure using a patient’s own bone marrow stem cells is recruiting participants at the first two study sites. . . . → Read More: Trial to Test Stem Cells for Treating Heart Failure

Novartis Acquires Sickle-Cell Drug Developer

Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million. . . . → Read More: Novartis Acquires Sickle-Cell Drug Developer

Infusion-to-Oral Drug Delivery Company Acquired

A company with a technology for converting drugs given by intravenous infusion into pills and capsules was acquired Grünenthal Group, a provider of pain medications. . . . → Read More: Infusion-to-Oral Drug Delivery Company Acquired

Google Acquires Visual Interaction Tech Company

Google is acquiring Eyefluence Inc., developer of a technology that allows individuals to interact with computers, phones, and other devices using only their eyes. . . . → Read More: Google Acquires Visual Interaction Tech Company

Juno Acquires Biotech, Licenses Cell Sequencing Tech

Scanning electron micrograph of a human T-cell lymphocyte (National Institute of Allergy and Infectious Diseases, NIH)

11 January 2016. Juno Therapeutics is gaining single-cell sequencing technology for cancer immunotherapies through the buy-out of biotechnology company AbVitro Inc., and licensing part of that technology to pharmaceutical company Celgene Corp. The AbVitro acquisition is valued at . . . → Read More: Juno Acquires Biotech, Licenses Cell Sequencing Tech